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Abstract
Background: As economic considerations become more important in healthcare reimbursement, decisions about
the further development of medical innovations need to take into account not only medical need and potential
clinical effectiveness, but also cost-effectiveness. Already early in the innovation process economic evaluations can
support decisions on development in specific indications or patient groups by anticipating future reimbursement
and implementation decisions. One potential concept for early assessment is value-based pricing.
Methods: The objective is to assess the feasibility of value-based pricing and product design for a hypothetical vascular
closure device in the pre-clinical stage which aims at decreasing bleeding events. A deterministic decision-analytic
model was developed to estimate the cost-effectiveness of established vascular closure devices from the perspective of
the Statutory Health Insurance system. To identify early benchmarks for pricing and product design, three strategies of
determining the product’s value are explored: 1) savings from complications avoided by the new device; 2) valuation of
the avoided complications based on an assumed willingness-to-pay-threshold (the efficiency frontier approach); 3) value
associated with modifying the care pathways within which the device would be applied.
Results: Use of established vascular closure devices is dominated by manual compression. The hypothetical vascular
closure device reduces overall complication rates at higher costs than manual compression. Maximum cost savings of
only about €4 per catheterization could be realized by applying the hypothetical device. Extrapolation of an efficiency
frontier is only possible for one subgroup where vascular closure devices are not a dominated strategy. Modifying care
in terms of same-day discharge of patients treated with vascular closure devices could result in cost savings of €400-600
per catheterization.
Conclusions: It was partially feasible to calculate value-based prices for the novel closure device which can be
used to inform product design. However, modifying the care pathway may generate much more value from
the payers’ perspective than modifying the device per se. Manufacturers should thus explore the feasibility of
combining reimbursement of their product with arrangements that make same-day discharge attractive also for
hospitals. Due to the early nature of the product, the results are afflicted with substantial uncertainty.
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Background
As economic considerations become more important
in healthcare reimbursement, decisions about the fur-
ther development of medical innovations need to take
into account not only medical need and potential
clinical effectiveness, but also the cost-effectiveness of
a new drug or medical device. It has been proposed that
already in an early phase of the innovation process,
economic evaluations can support decisions on further
development in specific indications or patient groups by
anticipating future reimbursement and implementation
decisions [1, 2]. Early assessment and estimation of health
and economic outcomes are vital for making these deci-
sions, and modeling techniques can be used to achieve
this [3, 4].
One potential concept for early assessment is value-
based pricing. It can be used to evaluate the additional
value that can be achieved by adopting an innovative med-
ical technology and to set a price relative to that value [5].
The question of what constitutes “value” of health tech-
nologies is a matter of unresolved debate (for Germany,
see e.g. [6–8]). Following Sussex et al., value-based pricing
requires an agreement about how the relevant benefits
and costs are identified, measured, valued, aggregated, and
used in decisions [9]. One central attribute of value of
new health technologies is the health gain it provides.
Value-based pricing is frequently assumed to involve
comparing the incremental cost-effectiveness ratio of
the novel technology with a threshold for cost-effectiveness
defined by the decision maker [10]. Given that cost-effect-
iveness varies between patient subgroups, it is sens-
ible for innovators to calculate a menu of prices to
determine the patient group in which their interven-
tion is most likely to be cost-effective [10, 11]. Fur-
thermore, if used early in research and development
(R&D), economic evidence might also be useful for
value-based product design. Here, development activ-
ities are oriented towards attributes which are most
valuable to those who decide about the innovations’
reimbursement and implementation in clinical
practice.
The German Institute for Quality and Efficiency in
Healthcare (“Institut für Qualität und Wirtschaftlichkeit
im Gesundheitswesen”, IQWiG) proposes using an “effi-
ciency frontier” based on the cost-effectiveness within a
medical condition as a benchmark of the German Statu-
tory Health Insurance (SHI) fund’s valuation of an
innovation [12]. Traditionally, measuring “efficiency” of
health services in Germany does not imply comparing
a new treatment’s cost-effectiveness to any threshold
value, but rather assessing whether one alternative is
dominated. Thus, prices for which a new technology
would be cost-saving or at which it incurs the same
incremental cost per health outcome as the most effective
existing technology, may serve as two benchmarks of
value in the German context.
A recent systematic review by Markiewicz et al.
[13] provides an overview of applied early assessment;
there are, however, few case studies on early assess-
ment in the context of the German SHI system avail-
able in the literature. This manuscript provides a
case-study for value-based pricing and product design
in the area of cardiovascular diseases which constitute
a substantial part of the economic burden of disease
in industrialized countries such as Germany.
The standard therapy for diagnosing and treating cor-
onary diseases in Germany is cardiac catheterization via
a femoral artery access. In 2011, around 1.2 million diag-
nostic and 600,000 interventional (incl. transcatheter
aortic valve implantations) heart catheterizations were
performed in German hospitals [14]. To reduce time to
normalization of hemostasis and sheath removal, various
vascular closure devices (VCDs) were developed as an
alternative to commonly applied manual compression
[15–19]. Over 330,000 VCDs were used in inpatient care
in Germany in 2011. After diagnostic catheterization,
about 30 % of patients received a VCD, after percutan-
eous coronary intervention (PCI) about 45 %, and after
transaortic valve transplantation (TAVI) 56 %, respect-
ively [20]. A number of health economic evaluations,
identified in a qualitative review, analyze closure devices,
with controversial results regarding cost-effectiveness.
The overall notion is that VCDs reduce time to
hemostasis, which may lead to earlier ambulation and
cost-savings. However, severe complications and associ-
ated follow-up costs seem to increase with the use of
VCDs [15, 21–27].
One area of medical innovation in this field is to
develop novel VCDs, which prevent bleeding compli-
cations after sheath removal. Similar devices are
currently developed by German researchers in cooper-
ation with industry partners and sponsorship by the
German Federal Ministry of Education and Research.
The purpose of this study is to provide an example of
using value-based pricing and product design in the
early economic evaluation of an innovative VCD for
cardiac diagnosis and interventions in which methods
of regenerative medicine are used to reduce the number of
bleeding complications. Given the early development stage
of the new device, the aim was not to develop a complex,
fully probabilistic model which would be required to pro-
vide economic evidence for a national coverage and reim-
bursement decision. Instead, the aim was to generate an
early estimate of value from an Statutory Health Insurance
(SHI) perspective to identify attractive target patient
groups, inform tentative value-based prices for differing as-
sumptions of effectiveness, and derive implications for in-
cluding such value considerations into product design.
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Methods
Model structure
A decision tree is used to depict relevant access site re-
lated complications following coronary angiography or
percutaneous coronary interventions and subsequent
therapies (Fig. 1). The alternative methods to achieve
hemostasis after sheath removal are manual compression
and application of VCDs. Manual compression (MC) is
chosen as a comparator in accordance with existing
economic evaluations, because this is the standard
method to stop bleeding when smaller sheath sizes
are used [15, 21–25, 27]. Interventions requiring large
sheath sizes (>18 French), such as transcatheter aortic
valve implantations, are not included in the model as
hemostasis methods apart from VCD are not comparable
(surgical arteriotomy vs. manual compression) [28, 29].
The comparator ‘vascular closure device’ represents
the mean costs and effects of the variety of devices cur-
rently used in German inpatient care and serves as a
benchmark for the novel device. The novel device is
considered in the analysis as a hypothetical scenario: a
new comparator for which the effectiveness is varied be-
tween that of existing VCDs and a VCD with 100 % ef-
fectiveness, i.e. zero bleeding complications. A time
horizon of 24 h is chosen in accordance with published
studies and expert opinion, which covers the time from
sheath removal to cure of all complications and hospital
discharge [22, 23, 30, 31].
Following German guidelines for health economic
evaluation, this study aimed at assessing costs from a so-
cietal perspective [32]. Given that the majority of pa-
tients undergoing coronary catheterization is older than
65 years and can therefore assumed to be retired [33],
indirect costs due to loss of productivity were consid-
ered less relevant. Also, no direct non-medical costs
(particularly travel costs to point of care) were identified
which differ across the strategies and equally no differ-
ences between direct medical costs not covered by the
German SHI. Therefore, this study assesses costs from
the health care system perspective. Only inpatient treat-
ment of complications is relevant for this assessment as
the majority of complications and costs incur at hospital.
Given the short time horizon and the acute nature of
complications, the intervention is modeled as a decision
tree ([34], p. 23). Effectiveness is measured by the total
number of complications averted per catheterization in
each respective case. All data in the model are point es-
timates. Discounting effects and costs is not necessary as
they occur within 24 h. All calculations are carried out
using MS Excel 2007.
The starting point of the model is immediately
after sheath removal and either beginning of manual
Fig. 1 Decision tree. Not shown is the decision arm depicting a failure of the vascular closure device
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compression or insertion of a VCD. Patients either
remain complication free or develop one or several
of the following complications: hematoma, retroperitoneal
hemorrhage, arteriovenous fistula, pseudoaneurysm, limb
ischemia/arterial stenosis, and infection. These complica-
tions are compiled from the literature and are considered
relevant for identifying the effectiveness and safety of clos-
ure devices [15–17, 19, 21, 24–26, 35]. Furthermore, com-
plications are validated by clinical experts. In case of VCD,
the decision tree contains an extra arm for the possibility
of device failure [15, 16, 18, 23, 24, 26, 35]. It is assumed
that manual compression is applied to achieve hemostasis
after VCD failure [15, 16, 26]. Complications are modeled
independently. We assume that there are no recurrences
and that every complication - with the exception of minor
hematomas and minor retroperitoneal hemorrhages - is
treated immediately [15, 21, 26].
Effectiveness of VCDs compared to manual compres-
sion is measured as the number of averted complications
per catheterization. This method has been used previ-
ously in meta-analyses and economic evaluations on
closure devices [15, 18, 25, 26]. For a conservative esti-
mate of effectiveness, only hematomas graded as large
are included in the analysis, whereas hematomas graded
as small and medium are not considered; it is assumed
that large graded hematomas have a similarly severe im-
pact on patients’ well-being as the other complications
considered in the analysis [16]. In the VCD arm of the
analysis, also the number of complications due to man-
ual compression after failure of the device is considered.
Clinical parameters
We identified five meta-analyses containing data on
complications associated with manual compression
and VCDs [15–19]. The most recent meta-analysis is
chosen as data source because it contains the largest
number of patients and trials and follows the meth-
odological recommendations of the Cochrane Collab-
oration [16]. The study compares the safety and
efficacy of various VCDs after transfemoral diagnostic
or interventional angiography with manual compres-
sion. Thirty-one prospective, randomized trials from
1992 to 2008 with 7,528 patients are included. How-
ever, high-risk patients were excluded in most studies.
Collagen-based and suture mediated devices are in-
corporated in the analysis, and sheath sizes range
from 3 to 10 French. The chosen meta-analysis pro-
vides probabilities for all complications, except ar-
teriovenous fistulae. Data are reported separately for
diagnostic and interventional catheterization.
Data on the probability of developing an arterioven-
ous fistula are extracted from a pooled analysis of
randomized trials on the use of AngioSeal after inter-
ventional catheterizations, which includes 10,113 pa-
tients [21]. Probabilities for treatment of hematomas
with blood transfusion are gained from a meta-
analysis of 27 studies with a total of 3,010 participat-
ing patients [15]. Manual compression after diagnostic
or interventional catheterization is compared with the
use of hemostasis devices (VasoSeal, Kensey Nash).
Due to a lack of published data, the probability for
treating retroperitoneal hematomas with blood trans-
fusions, endovascular intervention (embolization or
stent-graft), or vascular surgical intervention is based
on a clinical expert’s opinion [36, 37]. To account for
higher uncertainty, this parameter received special at-
tention in the sensitivity analysis. It is assumed that
all other complications are treated with one standard
therapy, which was chosen in accordance with pub-
lished literature and clinical experts’ opinions [15, 16,
26, 38–40]. Tables 1 and 2 provide an overview of
clinical parameters used in the analysis.
Table 1 Complication rates
Diagnostic & Interventional Hematoma AVF PSA RPH Limb Ischemia Infection
VCD 4.56 % 0.83 % 1.60 % 3.79 % 0.31 % 0.61 %
MC 5.08 % 0.20 % 1.59 % 2.91 % 0.00 % 0.22 %
Source (13) (18) (13) (13) (13) (13)
Diagnostic
VCD 4.20 % 0.83 % 0.90 % 4.40 % 0.00 % 0.10 %
MC 5.70 % 0.20 % 0.00 % 5.30 % 0.00 % 0.10 %
Source (13) (18) (13) (13) (13) (13)
Interventional
VCD 4.40 % 0.83 % 2.60 % 3.60 % 0.30 % 0.90 %
MC 4.80 % 0.20 % 2.50 % 2.40 % 0.00 % 0.30 %
Source (13) (18) (13) (13) (13) (13)
Data on AVF are for interventional catheterization only
AVF arteriovenous fistula, MC manual compression, PSA pseudoaneurysm, RPH retroperitoneal hemorrhage, VCD vascular closure device
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Costs
All costs in the model are obtained as reimbursement
rates for diagnosis-related groups (DRGs) from the
German Hospital Reimbursement Institute (“Institut für
das Entgeltsystem im Krankenhaus”, InEK) [33]. DRGs are
chosen because they best reflect the costs borne by statu-
tory health insurance and are used regularly in the litera-
ture to calculate inpatient costs [40, 41].
We analyze the 2010 DRG statistic provided by InEK
to identify DRGs that are associated with the procedure
code for VCDs. In a second step, these DRGs are nar-
rowed down by incidence of ICD-10 diagnosis codes for
all relevant complications [42]. The identified DRGs are
validated by the controlling department of a university
hospital. Table 3 shows all groups, which are considered
as best representatives of the costs incurred by compli-
cations. Basic DRGs F49G (diagnostic) and F24B/ F19C
(interventional) are used for the reimbursement of
catheterization without complications. Given that the
basic DRGs are the same for manual compression and
use of VCD, cost differences result from subsequent
complications. Treatment of complications is either re-
imbursed by a distinct DRG (infection treatment, endo-
vascular intervention/ vascular surgery) or covered by a
higher weighted DRG of catheterization (F49A and F24A/
F19A). Costs attributable to complications are then
calculated as the difference between the higher weighted
and the lower weighted DRG of catheterization. The costs
of VCDs per se are not separately reimbursed through the
DRG-system. The reimbursement for achieving hemostasis
is included in the basic DRG for diagnostic or interven-
tional catheterization and is the same for all methods.
The costs for diagnostic and interventional catheteri-
zations combined are calculated as a weighted average
(1:2), which was derived from the proportion of diagnos-
tic and interventional catheterizations enclosed in the
meta-analysis by Biancari et al. [16]. All costs are re-
ported in Euros (€) of the financial year 2010 and
rounded to the nearest euro. Table 4 shows all relevant
cost data.
Analysis
The costs and effects of existing VCDs compared to
manual compression are calculated for a combination
of diagnostic and interventional catheterizations (base
case). To explore which patient populations are suit-
able target groups for the novel device, costs and
effects are calculated separately for diagnostic and
interventional catheterizations. Scenario-analysis is con-
ducted because of evidence that larger sheath sizes used
for interventional compared to diagnostic catheterizations
result in higher complication rates [16]. Furthermore, use













VCD 0.20 % 1.00 % 1.00 % 100 % 100 % 100 %
MC 0.30 % 1.00 % 1.00 % 100 % 100 % 100 %
Source (12) Clinical expert Clinical expert Clinical expert Clinical expert Clinical expert
VCD failure 3.60 % Source (13)
AVF arteriovenous fistula, MC manual compression, PSA pseudoaneurysm, PTA percutaneous transluminal angioplasty, RPH retroperitoneal hemorrhage, US ultrasound,
VCD vascular closure device
Table 3 G-DRG description
Rationale DRG Name
Basic DRGs
Diagnostic w/o complications F49G Invasive cardiologic diagnostic without complications
Interventional w/o complications F24B Percutaneous coronary angioplasty without complications
F19C Percutaneous transluminal intervention at the heart
without complications
Higher weighted DRGs (blood transfusion, ultrasound-guided
compression, gluing, and percutaneous transluminal angioplasty)
Diagnostic w/o complications F49A Invasive cardiologic diagnostic with major complications
Interventional w/o complications F24A Percutaneous coronary angioplasty with major complications
F19A Percutaneous transluminal intervention with major complications
Distinct DRGs for complications
Treatment of infection T61B Postoperative infection
Surgery for vascular complications F08E Reconstructive vascular intervention without complications
G-DRG German diagnosis-related group
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of closure devices is recommended primarily after inser-
tion of large sheath sizes beginning at 7 French. According
to the 2011 statistics of DRG reimbursement in Germany,
about 30 % of patients receive a VCD after diagnostic
catheterization and 45 % after interventional cathe-
terization [20].
To assess the potential value of different specifications
for the innovative device in terms of reduced costs at-
tributable to complications, we change the effectiveness
of vascular closure devices in a scenario-analysis (ceteris
paribus). As the novel device is in the pre-clinical stage,
only assumptions can be made regarding its effectiveness
in preventing complications in accordance with the
manufacturer. The novel device is supposed to decrease
complication rates of hematomas and retroperitoneal
hemorrhages (bleeding events); thus, we decrease rates
in steps of 10 % until all bleeding complications are
averted. Potential cost savings due to higher effectiveness
in preventing bleeding events are calculated as the dif-
ference in costs attributable to complications of estab-
lished VCDs and the novel device. In addition, we
change all other complication rates to investigate which
complications have the strongest impact on costs. We
conduct a deterministic sensitivity analysis of the base
case model to assess the impact of each effect parameter,
including the probability of having no complications, on
costs. To achieve this, each effect parameter is varied
separately in the range of the upper and lower 95 % con-
fidence limit as reported by Biancari et al. [16]. The
range of costs is plotted in form of a tornado chart.
The German IQWiG recommends using the cost-
effectiveness of current care as a benchmark of willing-
ness to pay for a health gain [43]. To assess the potential
value of a device designed to prevent bleeding com-
plications in terms of willingness to pay for a health
gain, we estimate the incremental cost effectiveness
ratios (ICERs) of using closure devices compared with
manual compression as far as possible for the different
target groups. Given that no consistent estimates of
health-related quality of life were identified for the differ-
ent complications and given that the IQWiG does not
specify methods of aggregating and valuing different end-
points, the ICERs were calculated for the number of
averted complications per catheterization.
Finally, we assess a potential further way how the use
of the novel device could be valuable for the SHI. Be-
cause of evidence that cost savings due to same-day dis-
charge of patients treated with VCDs after diagnostic
catheterization are possible [22, 23], we estimate poten-
tial savings for the German context in a secondary ana-
lysis. From the DRG for diagnostic catheterization used
in our model (F49G), the reduction of resource costs is
calculated by extracting parameters reflecting costs possibly
avoided by earlier discharge (ward, intensive care unit) [44].
Alternatively, reimbursement savings are calculated as the
difference between inpatient (DRG F49G) and outpatient
(doctors’ fee scale: positions 13542, 01520, 34291, 40300)
reimbursement for diagnostic catheterization [45].
Results
Costs and effects of existing VCDs
In the base-case analysis, the manual compression strat-
egy yields total costs per catheterization of €3,667. Of
these costs, €68 are due to the 0.10 complications per
catheterization. The costs of the VCD strategy sum up to
€3,706 per catheterization, whereas €107 of these costs
are associated with 0.12 complications per catheterization.
The scenario analysis of diagnostic catheterization re-
sults in incremental costs of €77 and a reduction of
0.0084 complications per catheterization for the VCD
strategy when compared to manual compression. The
interventional catheterization scenario shows additional
€36 and additional 0.023 complications per catheterization
in the VCD group. Table 5 provides an overview of
Table 4 Cost data
Treatment Type of catheterization Total costs (€) Cost
With complications W/o complications Difference (€)
Blood transfusion/PTA Diagnostic F49A: 6.385,32 F49G: 1,085.33 5,299.99
Interventional F24A: 7.741,65 F24B: 5.108,25 2,633.40
Diagnostic & interventional 3,522.26
US-guided compression/gluing Diagnostic F49A: 6.385,32 F49G: 1,085.33 5,299.99
Interventional F19A: 7.063,48 F19C: 4.603,30 2,460.18
Diagnostic & interventional 3,406.78
Endovascular int./Vascular surgery Diagnostic, interventional, diagnostic
& interventional
F08E: 6,834.49 € -
Systemic antibiotic treatment Diagnostic, interventional, diagnostic
& interventional
T61B: 1,735.05 € -
Costs for the diagnostic & interventional group are a weighted average of diagnostic and interventional costs (1:2)
G-DRG German diagnosis-related group, int. intervention, PTA percutaneous transluminal angioplasty, US ultrasound
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absolute and incremental costs and effects. Positive values
of incremental cost effectiveness mean that under MC
complications are prevented compared to VCD; a positive
signal thus represents a more favorable outcome of MC
compared to VCD.
Potential savings from avoided complications
Figure 2 illustrates the effect of improving the effective-
ness of VCDs in terms of averted complications. For the
base-case, a 100 % prevention of hematomas and retro-
peritoneal hemorrhages has the lowest effect on costs
resulting from complications. Cost savings for hematomas
and retroperitoneal hemorrhages are €4 per catheterization
in total. Preventing all pseudoaneurysms would have the
largest potential for savings with an amount of €53 per
catheterization (Table 6).
To assess whether cost savings from hematoma and
retroperitoneal hemorrhage depend on the type of
catheterization, complication rates are also varied in
diagnostic and interventional scenarios. The result is
similar to base-case analysis with total savings of €6 and
€4, respectively.
The deterministic sensitivity analysis of parameter
variations within their 95 % confidence intervals shows
that the probability for blood transfusion in case of
hematoma in the manual compression strategy has the
largest effect on incremental costs. Results also are espe-
cially sensitive for the probability of developing a pseu-
doaneurysm in both strategies. Variables estimated by a
clinical expert apparently do not considerably influ-
ence incremental costs. Figure 3 shows results of the
sensitivity analysis.
Potential willingness to pay for avoided complications
Both for the base-case and for interventional procedures,
established VCDs incur higher costs and more


















MC 0.100 3,667 0.016 39 Dominated
VCD 0.116 3,706
Diagnostic MC 0.113 1,105 −0.008 77 9,142
VCD 0.105 1,182
Interventional MC 0.102 4,930 0.023 36 Dominated
VCD 0.125 4,966
ICER incremental cost effectiveness ratio, prev. prevented
Fig. 2 Change in total complication costs per catheterization by change in effectiveness (base-case). Hematoma. Retroperitoneal
Hemorrhage. Arteriovenous Fistula. Pseudoaneurysm. Limb ischemia/arterial stenosis. Infection
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complications compared to MC so that they are a domi-
nated strategy. It is therefore not possible to use the
IQWiG-benchmark for valuing novel drugs [43] and to
extrapolate the ICER of the most effective current treat-
ment as a benchmark for an acceptable cost-effectiveness
ratio for a novel device.
If closure devices are used after diagnostic cathe-
terization, they are associated with fewer complications
and higher costs. This is due to the fact that the compli-
cations they are associated with are more costly than
those of MC. Assuming that all complications are simi-
larly severe from a medical and patient perspective so
that effectiveness can be measured by the number of
complications avoided, an ICER could be calculated
which amounts to €9,142 per averted complication.
As specified by the manufacturer, the new device is de-
signed to prevent bleeding complications. Comparing a
hypothetical device with neither hematoma nor retro-
peritoneal hemorrhage with manual compression results
in a lower number of complications and higher costs for
all three scenarios (base case: 35€/-0,064 complica-
tions/ICER €547 per averted complication, diagnostic:
71€/-0,091 complications/ICER €780 per averted complica-
tion, interventional: 32€/-0,053 complications/ICER €604
per averted complication) [43].
Potential value of modifying the pathway of care
The novel hypothetical device is assumed to minimize
bleeding complications, especially after interventions
with large sheaths, which makes same-day discharge
safer than with existing VCDs. In Germany however, pa-
tients undergoing interventional catheterization have to
stay at hospital for observation for at least 24 h, regard-
less of the method used for achieving hemostasis. In the-
ory, same-day discharge is possible for patients treated
with a VCD after diagnostic catheterization; however,
this approach does not seem to be common German
practice, as inpatient stay is covered by DRGs for diag-
nostic catheterization. In 2011, just about 2.6 % of diag-
nostic catheterizations coded in DRG F49G were carried
out on a day care basis [46].
One potential indicator of the potential value of modify-
ing the care pathway towards same-day discharge can be
found within the DRGs for interventional and diagnostic
procedures which include cost for hotel and general wards
at an amount of approximately €400 per patient. These
costs could be avoided by same-day discharge. A second
point of orientation for potential savings from same-day
discharge can be taken from ambulatory (rather than in-
patient) reimbursement for the procedures which is about
600€ lower than the DRG reimbursement.
Discussion
Using the analysis for value-based pricing and
product design
By increasing the effectiveness of closure devices, cost
savings are possible. Price negotiations with health insur-
ance companies could be based on the aim to transfer
these into reimbursement rewards for manufacturers,
for example, in the form of premiums on specific DRGs
for coronary catheterization. These premiums could rep-
resent a price up to which the use of the hypothetical
device is a cost-saving strategy compared to the standard
approach; statutory health insurers would not be at a fi-
nancial disadvantage but rather offer additional benefit
to patients and doctors.
In this analysis, only cost savings of €4 per cathe-
terization could be obtained if the novel device was de-
signed in a way that 100 % of bleeding complications
could be avoided. Applying value-based pricing would
lead to a premium of up to only €4. Changing the R&D
strategy towards designing a product that would be asso-
ciated with a reduction of other complications than
bleeding (such as pseudoaneurysms and arteriovenous
fistulae) might be desirable as cost savings are higher
there. For example, preventing all pseudoaneurysms
would increase the value-based price to €53, which is
still a modest price markup.
A second possible way to deduce a value-based price
is to extrapolate the efficiency frontier as proposed by
the German IQWiG. Assuming a willingness-to-pay as
high as the current treatment standard, a premium of up
to €835 per diagnostic catheterization might be realized
in reimbursement negotiations. This would represent a
price where the use of the hypothetical device is still a
cost-effective strategy compared to established products.
It is unclear, though, whether the willingness-to-pay for
additional effectiveness of health insurance funds corre-
sponds with the IQWiG concept. Using willingness-to-
pay thresholds is more likely to be relevant for product
design in the case of decision makers with more expli-
citly stated values and methods like the National Insti-
tute of Health and Clinical Excellence in the UK.
A third way to use this analysis is to identify reim-
bursement or care scenarios in which the novel device
would be valuable from a SHI perspective. The study
demonstrated that considerable cost savings (€400-600
per patient) are possible if patients are discharged on the
Table 6 Cost savings by complication
Complication 100 % averted Cost savings per catheterization (€)
Hematoma 1
Retroperitoneal hemorrhage 4
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day of catheterization. However, it is likely that from a
hospital perspective the decrease of reimbursement reve-
nues is higher than the resource savings due to earlier
discharge; hospitals are likely to have financial incentives
not to discharge patients on the day of catheterization.
To account for these results, the value-based pricing
strategy could be extended beyond the scope of the de-
vice per se to modify care pathways.
Such an approach is only likely to be acceptable to cli-
nicians and patients if complications can be reduced to
an amount that it is considered safe to discharge patients
immediately. The meta-analysis identified during this
study revealed that the application of VCDs increases the
risk for severe complications - especially limb ischemia/
arterial stenosis and infection. To ensure that the novel
device is reimbursed and implemented in clinical practice,
these complications should be accounted for in the prod-
uct development process.
Comparison of results with existing evidence
The cost studies by Mann et al. [26] and Reddy et al.
[24] report higher costs for the VCD strategy compared
to manual compression, as in our study. However, differ-
ences in cost result in costs of the medical device itself,
which are relevant from the hospital’s perspective. Costs
of the device itself cannot be assessed in this analysis, as
medical devices for hemostasis are not reimbursed on a
fee for service basis in the German DRG-system. Similar
Fig. 3 Tornado chart. MC, manual compression; RPH, retroperitoneal hemorrhage; VCD, vascular closure device
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results, however, would be expected, when employing re-
imbursement premiums for the hypothetical device.
Studies assuming same-day discharge of most patients in
the VCD group conclude that using a device is a cost-
saving strategy [22, 23]. We do not include early discharge
as a structural assumption in the model. Secondary ana-
lysis, however, shows considerable potential cost savings.
If manual compression leads to significantly more compli-
cations than application of VCDs, the closure device
strategy is cost-saving as well [21].
We identified one other study where an incremental
analysis of costs and consequences is conducted. Similar
to the results of this analysis, Bos et al. [15] calculate an
ICER of $9,000 per averted complication for VCDs ver-
sus manual compression after diagnostic and interven-
tional femoral catheterization.
Strengths and limitations
To our knowledge, this is the first study evaluating the
feasibility of calculating value-based prices and providing
recommendations for value-based product design for in-
novative closure devices.
This study only included direct medical costs of in-
patient care on the basis of DRGs which provide an esti-
mate of the average costs assessed with the VCD’s
complications. However, decisions about the acquisition
of new closure devices are typically made by hospitals
within the context of the DRG system. This study
already addressed the role of potentially adverse incen-
tives implied by the DRG system. Further research
should explore the value from a hospital perspective be-
cause on this level.
The structure of the model is coherent with treatment
pathways in Germany and is validated by several clinical
experts. A time horizon of 24 h is chosen, which is ap-
propriate to reveal costs and consequences relevant for
inpatient analysis. Costs of the whole hospital episode
are considered in the analysis, which might also include
hospital stay longer than 24 h. To analyze costs and con-
sequences in outpatient care - for example work absen-
teeism due to complications - and consider long-term
effects of either manual compression or application of
VCDs, a longer time horizon would be required. Use of
closure devices in interventions with large sheath sizes
as used for transcatheter aortic valve implantations,
could not be considered as a subgroup analysis in the
model. Here, the alternative method to achieve hemostasis
compared to use of VCDs is surgical cutdown [29, 47, 48].
The benefit of using VCDs instead of open surgery in
transcatheter aortic valve implantations is difficult to esti-
mate as there is evidence on lower rates of vascular com-
plications and higher rates of bleeding events [29, 48].
Assumptions on the value of the outcome measure
needed to be made to calculate value-based prices. It
was assumed that patients value fewer complications
higher than more complications and that interval prop-
erty is given [12]. It is also assumed that the different
complications aggregated in the outcome measure have
a similar impact on patients’ wellbeing, which might not
be the case in clinical practice. The value for patients
might extend beyond this outcome measure. Patients are
reported to appraise methods of achieving hemostasis,
for example, regarding their ability to eat and difficulty
to urinate after catheterization [35, 49]. Further work is
necessary to assess the patients’ relative valuation of the
different outcomes and their willingness to pay out of
pocket for these aspects. Due to the lack of published
generic measures of quality of life after either manual
compression or insertion of a vascular closure, no cost-
utility analysis was developed. Also, the analysis focuses
on the German context where the willingness-to-pay
threshold currently proposed by IQWiG is not based on
quality-adjusted life years by default [12].
The efficiency frontier approach used in this analysis
has met substantial criticism. It has been argued that
there is no scientific or normative rationale for using the
cost-effectiveness of the current treatment standard as a
valid measure of willingness-to-pay. Addressing this
criticism is beyond the scope of this study. A detailed
discussion can be found in the statement of several German
health economists [50, 51] and by Drummond and Rutten
[52]. Further limitations of the IQWiG approach become
apparent in our analysis, as the efficiency frontier can only
be used to estimate the cost-effectiveness of a subgroup of
catheterizations; no recommendation on value-based prices
can be given for base case and interventional scenarios.
The efficiency frontier approach is applied nevertheless for
this early evaluation, because the analysis focuses on value-
based pricing in the German SHI system and no alternative
benchmark for Germany is currently available.
Further research could be conducted to refine the
model regarding the following issues: Data on complica-
tion rates are extracted from three meta-analyses. This
might distort results as different closure devices and
types of catheterization are included. Furthermore, the
data used in this early model are not sufficient to pro-
vide a detailed analysis of all VCDs currently used in
Germany. This was considered a reasonable starting
point because decisions about reimbursement rates in
Germany are typically oriented at methods in general ra-
ther than specific products used within them. However,
it would be desirable to extend this work and include
data on all comparators, in particular the most effective
one. Also, the meta-analyses include data from studies
conducted over 20 years ago. Treatment practice and ex-
perience in handling VCDs have evolved since then,
which might possibly lead to a higher effectiveness of
VCDs in the present than represented in the data. Data
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regarding death as a complication of vascular closure de-
vice use could not be identified. Also, death could not be
included in the chosen outcome measure ‘number of
averted complications’ as the impact of death on pa-
tient’s health is not comparable to the impact of the
other complications considered in the analysis. In gen-
eral, the mortality rate is approximately 0.1 % after diag-
nostic catheterization and about 1 % after interventional
catheterization [53–55]. The exclusion of death might
overestimate the effectiveness of closure devices given
that severe complications leading to death are more
common with this method. Also, no data on high-risk
patients with several co-morbidities or anticoagulation
therapy are available because these are typically excluded
from clinical trials. It is difficult to estimate in which dir-
ection results are distorted, as it is expected that patients
with severely calcified arteries are better treated with
manual compression. For very obese patients application
of VCDs might be more effective [16]. Assuming the
biggest possible price difference between DRGs with and
without complications might overestimate costs attribut-
able to complications. Furthermore, assuming that each
patient with an arteriovenous fistula, pseudoaneurysm,
limb ischemia, or infection is treated might lead to over-
estimation of the costs attributable to complications.
Also, a probabilistic instead of a deterministic model
could have been developed. It is the purpose of this
study to evaluate, how information on costs and effect-
iveness can be made usable to the manufacturer within a
short period of research. Construction of a probabilistic
model would be more time-consuming and beyond the
scope of this project. Also, structural uncertainty is ex-
pected to be so high that parameter uncertainty is not as
relevant as in other analyses. Also, it is unlikely that
large efforts for refining the model would have changed
the key finding that the potential savings from same-day
discharge are much higher than those from a reduced
number of complications.
Conclusions
Generally it appears feasible to develop recommenda-
tions for value-based prices and product design strat-
egies for novel closure devices on the basis of early
health economic modeling. In the process of early evalu-
ation, care pathways are identified and a potential for
cost-savings due to value-based modifications becomes
apparent: If the safety of discharging patients on the day
of catheterization can be established for the hypothetical
device, manufacturers should consider negotiating reim-
bursement arrangements based on the benefits from
savings they incur. Cost-savings due to early discharge
are more likely to provide an economic argument for
using closure devices than savings due to prevented
bleeding complications. Apart from the SHI perspective,
also the willingness of patients to privately pay for greater
comfort after interventions might be worth assessing by
manufacturers. Further research is necessary to further ex-
plore the contribution of early economic evaluation to a
value-based modification of care pathways and the role of
other factors in decision practice.
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